A Phase 1/2 interventional study of HBI-8000 in combination with nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer, sponsored by HUYABIO International, LLC.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by HUYABIO International, LLC. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.
Among the 142 studies testing nivolumab in Melanoma, this one is the 44th largest by enrollment, is one of 16 that started in 2016, is one of 17 in phase 1/2, and was the 33rd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 20 · Phase 4 4
First in 2006; this study’s year is marked. 16 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 50 across the 142 interventional studies. Of the 62 that completed or were terminated, 35 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 142 have an industry lead sponsor. The 10 most frequent:
HUYABIO International, LLC. is the lead sponsor of 12 studies on the registry; none are open to participants now.
HUYABIO International, LLC. has 2 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
13 of the studies testing nivolumab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT03685890Vastra Gotaland RegionEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 142 studies testing nivolumab in Melanoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC).
The primary objective of this study is:
-To evaluate the safety and tolerability of HBI-8000 when combined with a standard dose and regimen of nivolumab, and to evaluate frequency and severity of toxicities of this combination treatment
The secondary objectives of this study include:
Exploratory:
Dose Escalation (Phase 1b) will include up to 18 subjects, followed by Cohort Expansion (Phase 2) including up to 100 subjects (melanoma up to 60 subjects and NSCLC up to 40 subjects at MTD and/or RP2D.
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC).
The primary objective of this study is:
-To evaluate the safety and tolerability of HBI-8000 when combined with a standard dose and regimen of nivolumab, to determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) and to evaluate frequency and severity of toxicities of this combination treatment
The secondary objectives of this study include:
Exploratory:
-To investigate the kinetics and extent of histone acetylation in peripheral blood mononuclear cells (PBMC) at the RP2D of HBI-8000 (Phase 2 only)
Dose Escalation (Phase 1b) will include up to 18 subjects, followed by Cohort Expansion (Phase 2) including up to 100 subjects (melanoma up to 60 subjects and NSCLC up to 40 subjects) at MTD and/or RP2D.
HBI-8000 tablets will be administered at 20, 30, 40 mg/dose, orally twice a week until MTD or 40 mg in Phase 2, if MTD is not reached.
Nivolumab: 240 mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.
A treatment cycle consists of 28 days. Treatment continues until disease progression or unacceptable toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects were entered in the study only if they met all of the following criteria:
1. Adults at least 18 years of age. 2. (ECOG) performance status ≤1. 3.
c, Non uveal melanoma and NSCLC subjects whose disease progressed after achieving stable disease (SD) for at least 3 months, with partial response (PR) or complete response (CR) as the best response that was documented by imaging studies on previous treatment with a PD L1 inhibitor with proven efficacy (Phase 2 expansion). With Protocol Amendment 5, subjects with NSCLC were not eligible for enrollment.
4. Subject had at least one measurable target lesion as defined by v1.1 (RECIST 1.1). Melanoma subjects participating in the optional correlative substudy had tumor tissue available from a or unresectable site for PD L1 and correlative biomarker analysis.
5. All prior systemic therapy (chemotherapy, mutation targeting therapy, immune checkpoint therapy), or surgical or radiation treatment was completed at least 4 weeks before study drug* administration (2 weeks for palliative radiotherapy, 1 week for minor surgery), pending full recovery from therapy.
6. The following laboratory results within 7 days prior to study drug* administration: Adequate hematopoietic, electrolyte, hepatic, and renal laboratory findings as defined below: white blood cells (WBC) ≥3000/μL, neutrophils ≥1500/μL, ≥100x103/μL, ≥9.0 g/dL independent of transfusion, creatinine ≤1.5 mg/dL, (AST) and alanine aminotransferase (ALT) ≤3 × (ULN), alkaline phosphatase ≤2.5 x ULN (unless bone metastases present), ≤1.5 × ULN (unless known Gilbert's disease, where value must be ≤3 × ULN), and serum albumin ≥3.0 g/dL.
7. ≥12 weeks. 8. A negative serum pregnancy test at baseline for women of .
9. Were willing to abstain from heterosexual activity or practice physical barrier prior to time of study entry to at least 5 months after the last day of treatment.
10. Had the ability to understand and the willingness to sign a written document.
Exclusion Criteria
Subjects who fulfilled any of the following criteria at screening were not eligible for admission into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.
Drug: HBI-8000 in combination with nivolumab
Drug pages: Tucidinostat · Nivolumab
Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks. Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice.
Also known as: For HBI-8000: Chidamide, CS055; for nivolumab: OPDIVO
Number of Patients Who Experienced at Least One DLT During the DLT Assessment Period for MTD Determination
The dose escalation schema of HBI 8000 followed the conventional 3+3 design. The starting dose was HBI 8000 20 mg twice a week. Dose escalation to 30 mg or 40 mg was determined by observation of DLT. At each dose level, a minimum of 3 subjects evaluable for DLT were enrolled. If 0 of the initial 3, or no more than 1 in a total 6 subjects experienced DLT, escalation to the next higher dose was allowed.
Time frame: First 28 days
Objective Response Rate (ORR) in All Patients Treated at RP2D
Percentage of patients with complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Time frame: From screening for baseline assessment to the date of CR or PR assessed, up to approximately 4 years and 7 months
Disease Control Rate (DCR) in All Patients Treated at RP2D
Percentage of patients with complete response (CR), partial response (PR) or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Time frame: From screening for baseline assessment to the date of best response (CR, PR, or SD) on study, up to approximately 4 years and 7 months
Duration of Response (DoR) in All Patients Treated at RP2D
Time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death.
Time frame: From the date of CR or PR until the date of PD, or until the date of death, up to approximately 4 years and 7 months
Progression-Free Survival (PFS) in All Patients Treated at RP2D
Time from the date of first dose of HBI-8000 until tumor progression by site reported RECIST 1.1, or clinical progression, or death, whichever occurs first. If tumor progression data include more than 1 date of progression, the earliest date will be used.
Time frame: From the date of first dose of HBI-8000 until tumor progression by site reported RECIST 1.1, or clinical progression, or death, whichever occurs first, up to approximately 4 years and 7 months
Pharmacokinetic - Cmax (Single Dosing)
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Time frame: From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1, at 24 hours on Cycle 1 Day 2 (no dose administered)
Pharmacokinetic - Cmax (Repeat Dosing)
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Time frame: From predose to 7 hours postdose on Cycle 2 Day 1
Pharmacokinetic - AUC(0-7) (Single Dosing)
Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.
Time frame: From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1
Pharmacokinetic - AUC(0-7) (Repeat Dosing)
Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.
Time frame: From predose to 7 hours postdose on Cycle 2 Day 1
Pharmacokinetic - AUC(0-24)
Area under the plasma concentration time curve from zero (predose) to 24 hours postdose, calculated by linear up/log down trapezoidal summation. Calculated for C1D1 only.
Time frame: From predose (0.5 hour prior to breakfast) on Cycle 1 Day 1 to 24 hours on Cycle 1 Day 2 (no dose administered)
Pharmacokinetic - Tmax (Single Dosing)
Time of Cmax, obtained directly from the observed concentration versus time data.
Time frame: From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1, at 24 hours on Cycle 1 Day 2 (no dose administered)
Pharmacokinetic - Tmax (Repeat Dosing)
Time of Cmax, obtained directly from the observed concentration versus time data.
Time frame: From predose to 24 hours postdose on Cycle 2 Day 1
QTcF Values >450 Msec
Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.
Time frame: 0 (predose) up to 4 hours postdose on C1D1 and C2D1
QTcF Increase > 30 Msec
Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.
Time frame: 0 (predose) up to 4 hours postdose on C1D1 and C2D1
Concentration Slope
Slope estimate between ΔQTcF and HBI 8000 concentrations
Time frame: 0 (predose) up to 4 hours postdose on C1D1 and C2D1
The first subject enrolled 18 August 2016 and the last subject enrolled 19 January 2021. All sites were located in the US.
| Milestone | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab |
|---|---|---|---|---|
| Started | 3 | 7 | 7 | 79 |
| Completed | 0 | 0 | 0 | 2 |
| Not completed | 3 | 7 | 7 | 77 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 5 |
| Withdrew: Death | 2 | 4 | 7 | 28 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 4 |
| Withdrew: Other - majority: completion of survival follow-up | 1 | 2 | 0 | 40 |
The dose escalation schema of HBI 8000 followed the conventional 3+3 design. The starting dose was HBI 8000 20 mg twice a week. Dose escalation to 30 mg or 40 mg was determined by observation of DLT. At each dose level, a minimum of 3 subjects evaluable for DLT were enrolled. If 0 of the initial 3, or no more than 1 in a total 6 subjects experienced DLT, escalation to the next higher dose was allowed.
| patients | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab |
|---|---|---|---|
| Number of Patients Who Experienced at Least One DLT During the DLT Assessment Period for MTD Determination | 0 | 0 | 2 |
Percentage of patients with complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
| Percentage of patients | Phase 1b and 2 HBI-8000 30 mg: Melanoma | Phase 1b and 2 HBI-8000 30 mg: NSCLC | Phase 1b and 2 HBI-8000 30 mg: RCC | Phase 1b and 2 HBI-8000 30 mg: Total |
|---|---|---|---|---|
| Objective Response Rate (ORR) in All Patients Treated at RP2D | 56.6 (42.3 to 70.2) | 22.7 (7.8 to 45.4) | 16.7 (0.4 to 64.1) | 44.4 (33.4 to 55.9) |
Percentage of patients with complete response (CR), partial response (PR) or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
| Percentage of patients | Phase 1b and 2 HBI-8000 30 mg: Melanoma | Phase 1b and 2 HBI-8000 30 mg: NSCLC | Phase 1b and 2 HBI-8000 30 mg: RCC | Phase 1b and 2 HBI-8000 30 mg: Total |
|---|---|---|---|---|
| Disease Control Rate (DCR) in All Patients Treated at RP2D | 84.9 (72.4 to 93.3) | 68.2 (45.1 to 86.1) | 66.7 (22.3 to 95.7) | 79.0 (68.5 to 87.3) |
Time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death.
| Weeks | Phase 1b and 2 HBI-8000 30 mg: Melanoma | Phase 1b and 2 HBI-8000 30 mg: NSCLC | Phase 1b and 2 HBI-8000 30 mg: RCC | Phase 1b and 2 HBI-8000 30 mg: Total |
|---|---|---|---|---|
| Duration of Response (DoR) in All Patients Treated at RP2D | NA (NA to NA) | 32.0 (15.9 to NA) | 89.4 (NA to NA) | NA (81.1 to NA) |
Time from the date of first dose of HBI-8000 until tumor progression by site reported RECIST 1.1, or clinical progression, or death, whichever occurs first. If tumor progression data include more than 1 date of progression, the earliest date will be used.
| Weeks | Phase 1b and 2 HBI-8000 30 mg: Melanoma | Phase 1b and 2 HBI-8000 30 mg: NSCLC | Phase 1b and 2 HBI-8000 30 mg: RCC | Phase 1b and 2 HBI-8000 30 mg: Total |
|---|---|---|---|---|
| Progression-Free Survival (PFS) in All Patients Treated at RP2D | 79.6 (24.9 to NA) | 10.1 (7.6 to 55.7) | 14.6 (7.6 to NA) | 34.7 (22.1 to 70.4) |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
| ng/mL | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab | Phase 2/HBI-8000 30mg in Combination With Nivolumab |
|---|---|---|---|---|
| Pharmacokinetic - Cmax (Single Dosing) | 104.9 ± 32.2 | 117.6 ± 34.0 | 259.3 ± 73.5 | 111.1 ± 52.2 |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
| ng/mL | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab | Phase 2/HBI-8000 30mg in Combination With Nivolumab |
|---|---|---|---|---|
| Pharmacokinetic - Cmax (Repeat Dosing) | NA ± NA | 112.8 ± 93.8 | 228.6 ± 72.9 | 96.79 ± 55.9 |
Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.
| ng*h/mL | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab | Phase 2/HBI-8000 30mg in Combination With Nivolumab |
|---|---|---|---|---|
| Pharmacokinetic - AUC(0-7) (Single Dosing) | 383.6 ± 8.9 | 341.5 ± 97.8 | 972.5 ± 124.2 | 402.1 ± 94.3 |
Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.
| ng*h/mL | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab | Phase 2/HBI-8000 30mg in Combination With Nivolumab |
|---|---|---|---|---|
| Pharmacokinetic - AUC(0-7) (Repeat Dosing) | NA ± NA | 392.2 ± 117.3 | 929.4 ± 89.0 | 433.0 ± 78.3 |
Area under the plasma concentration time curve from zero (predose) to 24 hours postdose, calculated by linear up/log down trapezoidal summation. Calculated for C1D1 only.
| ng*h/mL | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab | Phase 2/HBI-8000 30mg in Combination With Nivolumab |
|---|---|---|---|---|
| Pharmacokinetic - AUC(0-24) | 1590 ± 29.7 | 1734 ± 29.3 | 3690 ± 54.9 | 1605 ± 44.5 |
Time of Cmax, obtained directly from the observed concentration versus time data.
| h | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab | Phase 2/HBI-8000 30mg in Combination With Nivolumab |
|---|---|---|---|---|
| Pharmacokinetic - Tmax (Single Dosing) | 6.083 ± 0.9393 | 11.054 ± 9.4287 | 4.426 ± 1.9682 | 6.715 ± 6.5280 |
Time of Cmax, obtained directly from the observed concentration versus time data.
| h | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab | Phase 2/HBI-8000 30mg in Combination With Nivolumab |
|---|---|---|---|---|
| Pharmacokinetic - Tmax (Repeat Dosing) | NA ± NA | 5.833 ± 1.5190 | 5.613 ± 2.3897 | 6.693 ± 0.3244 |
Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.
| participants | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab |
|---|---|---|---|
| QTcF Values >450 Msec | 0 | 0 | 0 |
Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.
| participants | Phase 1/HBI-8000 20mg in Combination With Nivolumab | Phase 1/HBI-8000 30mg in Combination With Nivolumab | Phase 1/HBI-8000 40mg in Combination With Nivolumab |
|---|---|---|---|
| QTcF Increase > 30 Msec | 0 | 0 | 0 |
Slope estimate between ΔQTcF and HBI 8000 concentrations
| ms/mg/ml | HBI-8000 in Combination With Nivolumab Phase 1b |
|---|---|
| Concentration Slope | -0.02154 (-0.03426 to -0.008814) |
Collected over From the first dose of study treatment until end of safety follow-up, up to 5 years 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | 4/7 (57.1%) | 6/7 (85.7%) | 7/7 (100%) |
| Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | 7/7 (100%) | 4/7 (57.1%) | 7/7 (100%) |
| Phase 2: HBI-8000 30 mg in Combination With Nivolumab | 28/79 (35.4%) | 39/79 (49.4%) | 79/79 (100%) |
| Event | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab |
|---|---|---|---|---|
| ColitisGastrointestinal disorders | 1/3 | 0/7 | 1/7 | 0/79 |
| Systemic inflammatory response syndromeGeneral disorders | 1/3 | 0/7 | 0/7 | 0/79 |
| PneumoniaInfections and infestations | 1/3 | 1/7 | 0/7 | 4/79 |
| SomnolenceNervous system disorders | 1/3 | 0/7 | 0/7 | 0/79 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/3 | 0/7 | 1/7 | 3/79 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 2/7 | 0/7 | 2/79 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 1/7 | 0/7 | 2/79 |
| Angina pectorisCardiac disorders | 0/3 | 1/7 | 0/7 | 0/79 |
| Atrial fibrillationCardiac disorders | 0/3 | 1/7 | 1/7 | 0/79 |
| Cardiac arrestCardiac disorders | 0/3 | 0/7 | 1/7 | 1/79 |
| Event | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab |
|---|---|---|---|---|
| FatigueGeneral disorders | 2/3 | 5/7 | 3/7 | 52/79 |
| Weight decreasedInvestigations | 1/3 | 5/7 | 1/7 | 28/79 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 3/7 | 2/7 | 42/79 |
| NauseaGastrointestinal disorders | 2/3 | 3/7 | 3/7 | 44/79 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/3 | 0/7 | 1/7 | 11/79 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/3 | 4/7 | 3/7 | 31/79 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 4/7 | 4/7 | 37/79 |
| Oedema peripheralGeneral disorders | 1/3 | 4/7 | 2/7 | 29/79 |
| Lipase increasedInvestigations | 0/3 | 4/7 | 1/7 | 19/79 |
| Platelet count decreasedInvestigations | 0/3 | 4/7 | 3/7 | 42/79 |
| Age, Categorical(Participants) | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 1 | 40 | 45 |
| >=65 years | 2 | 4 | 6 | 39 | 51 |
| Sex: Female, Male(Participants) | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 3 | 35 | 40 |
| Male | 2 | 6 | 4 | 44 | 56 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 5 | 6 |
| Not Hispanic or Latino | 3 | 6 | 7 | 73 | 89 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 2 | 2 |
| White | 3 | 7 | 7 | 73 | 90 |
| Other | 0 | 0 | 0 | 2 | 2 |
| Not reported | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Phase 1b: HBI-8000 20 mg in Combination With Nivolumab | Phase 1b: HBI-8000 30 mg in Combination With Nivolumab | Phase 1b: HBI-8000 40 mg in Combination With Nivolumab | Phase 2: HBI-8000 30 mg in Combination With Nivolumab | Total |
|---|---|---|---|---|---|
| United States | 3 | 7 | 7 | 79 | 96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2016 to primary completion in Dec 2023, 87 months.
Results were first posted in Jul 2026, 2 years 7 months after primary completion.
Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 87 months is above that.
Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tucidinostat · Nivolumab
HUYABIO International, LLC.